Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 365b (miR-365b) is a small, non-coding RNA molecule belonging to the microRNA (miRNA) family, functioning primarily in the post-transcriptional regulation of gene expression by influencing mRNA stability and translation[3][4]. Like other miRNAs, it is transcribed as a precursor transcript that is processed into a mature form and incorporated into the RNA-induced silencing complex (RISC), where it binds target mRNAs via sequence complementarity causing translation inhibition or degradation[3]. miR-365b has been implicated in the regulation of cell proliferation, cell cycle arrest, and apoptosis in cancer contexts[1][5]. Specifically, it acts as a tumor suppressor in non-small cell lung cancer cells by targeting PPP5C, leading to reduced proliferation and increased apoptosis[1]. Moreover, its expression patterns serve as potential biomarkers in cancer classification studies, such as in brain metastases and multiple myeloma[2][7][5]. No direct interacting drugs or established mechanisms of action for drug targeting are reported to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 365b (miR-365b).